Literature DB >> 11129334

Molecular analysis of the TSC1 and TSC2 tumour suppressor genes in sporadic glial and glioneuronal tumours.

L Parry1, J H Maynard, A Patel, A K Hodges, A von Deimling, J R Sampson, J P Cheadle.   

Abstract

Reduced expression of the TSC2 tumour suppressor gene product, tuberin, has been reported in sporadic astrocytomas, suggesting that the TSC genes may play a role in formation of sporadic glial or glioneuronal tumours. We studied paired constitutional and tumour DNA samples from 100 patients with sporadic glial and glioneuronal tumours for loss of heterozygosity (LOH) at the TSC1 and TSC2 loci using a combination of seven previously reported and seven novel polymorphic markers. LOH was seen in 1/16 astrocytomas, 3/15 ependymomas, 5/16 gangliogliomas, 2/14 glioblastoma multiforme, 0/7 oligodendrogliomas, 0/7 tumours of mixed oligodendrocytic/astrocytic histology, 2/11 pilocytic astrocytomas and 0/1 subependymal giant cell astrocytomas informative at both loci. However, SSCP screening of all coding exons of the TSC1 or TSC2 genes in the tumours displaying LOH, and of both genes in 21 gangliogliomas, revealed no intragenic mutations. The lack of demonstrable inactivation of both alleles of either TSC gene in any of the tumours investigated suggests that they do not play a frequent role in the aetiology of sporadic glial or glioneuronal tumours.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129334     DOI: 10.1007/s004390000390

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  12 in total

Review 1.  Toward precision medicine in glioblastoma: the promise and the challenges.

Authors:  Michael D Prados; Sara A Byron; Nhan L Tran; Joanna J Phillips; Annette M Molinaro; Keith L Ligon; Patrick Y Wen; John G Kuhn; Ingo K Mellinghoff; John F de Groot; Howard Colman; Timothy F Cloughesy; Susan M Chang; Timothy C Ryken; Waibhav D Tembe; Jeffrey A Kiefer; Michael E Berens; David W Craig; John D Carpten; Jeffrey M Trent
Journal:  Neuro Oncol       Date:  2015-05-01       Impact factor: 12.300

2.  Tuberous sclerosis complex 2 loss of heterozygosity in patients with lung disease and cancer.

Authors:  Li Zhang; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Jiro Kato; Mary Haughey; Joseph R Fontana; Vincent C Manganiello; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

Review 3.  Epilepsy related to developmental tumors and malformations of cortical development.

Authors:  Eleonora Aronica; Peter B Crino
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

4.  Gastric Adenocarcinoma in Association with Tuberous Sclerosis: Case report.

Authors:  Saeed Ahmed; Ikram Burney; Sukhpal Sawhney; Mansour S Al-Moundhri
Journal:  Sultan Qaboos Univ Med J       Date:  2009-03-16

5.  Genetic and pathologic evolution of early secondary gliosarcoma.

Authors:  Kari-Elise T Codispoti; Stacy Mosier; Robert Ramsey; Ming-Tseh Lin; Fausto J Rodriguez
Journal:  Brain Tumor Pathol       Date:  2013-01-17       Impact factor: 3.298

6.  Targeted therapy in the treatment of malignant gliomas.

Authors:  Rimas V Lukas; Adrienne Boire; M Kelly Nicholas
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

7.  Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.

Authors:  Sanjukta Chakraborty; S M Azeem Mohiyuddin; K S Gopinath; Arun Kumar
Journal:  BMC Cancer       Date:  2008-06-06       Impact factor: 4.430

Review 8.  A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors.

Authors:  Ingmar Blumcke; Eleonora Aronica; Horst Urbach; Andreas Alexopoulos; Jorge A Gonzalez-Martinez
Journal:  Acta Neuropathol       Date:  2014-05-25       Impact factor: 17.088

9.  Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.

Authors:  Louis S Pymar; Fiona M Platt; Jon M Askham; Ewan E Morrison; Margaret A Knowles
Journal:  Hum Mol Genet       Date:  2008-04-07       Impact factor: 6.150

10.  Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer.

Authors:  Maria Tsoli; Carol Wadham; Mark Pinese; Tim Failes; Swapna Joshi; Emily Mould; Julia X Yin; Velimir Gayevskiy; Amit Kumar; Warren Kaplan; Paul G Ekert; Federica Saletta; Laura Franshaw; Jie Liu; Andrew Gifford; Martin A Weber; Michael Rodriguez; Richard J Cohn; Greg Arndt; Vanessa Tyrrell; Michelle Haber; Toby Trahair; Glenn M Marshall; Kerrie McDonald; Mark J Cowley; David S Ziegler
Journal:  Cancer Biol Ther       Date:  2018-10-09       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.